logo

VTVT

vTv Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.23 / 10
Netural

Fundamental analysis reveals subpar quality (3.2/10). Key concerns include a negative revenue-MV (-0.264) and an asset-MV deficit (-0.507), while factors like interest coverage ratio (15.5) and inventory turnover show some strength. The negative revenue and asset gaps outweigh positives, leading to a challenging fundamental outlook.

Fundamental(3.23)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight24.85%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value-100.00
Score3/3
Weight1.60%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.07%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight19.95%
1M Return8.99%
PB-ROE
Value-0.30
Score2/3
Weight26.71%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.15%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value-100.00
Score2/3
Weight0.18%
1M Return0.10%
Asset-MV
Value-0.51
Score0/3
Weight13.48%
1M Return6.58%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.70%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight19.15%
1M Return8.80%
Is VTVT fundamentally strong?
  • VTVT scores 3.23/10 on fundamentals and holds a Fair valuation at present. Backed by its -46.76% ROE, -166935.29% net margin, -4.87 P/E ratio, 1.62 P/B ratio, and 24.49% earnings growth, these metrics solidify its Netural investment rating.